Surgery for recurrent ovarian cancer

Area of Science:

• Gynecologic Oncology
• Surgical Oncology
• Clinical Management

Background:

• Recurrent ovarian cancer presents a poor prognosis with undefined optimal management strategies.
• Primary cytoreductive surgery improves survival in advanced ovarian cancer, prompting investigation into secondary surgery for recurrent or progressive disease.

Purpose of the Study:

• To evaluate the role and efficacy of secondary cytoreductive surgery in managing recurrent ovarian cancer.
• To determine if secondary surgery improves survival rates compared to chemotherapy alone in recurrent ovarian cancer.

Main Methods:

• Review of available data and clinical experiences regarding secondary cytoreductive surgery in ovarian cancer.
• Analysis of patient outcomes based on disease status (recurrent vs. progressive) and recurrence-free interval.

Main Results:

• Secondary surgery is not recommended for patients whose disease progresses or stabilizes during primary adjuvant chemotherapy.
• The most promising results for secondary surgery are observed in patients with recurrent ovarian cancer and a recurrence-free interval of at least 1 year.
• While feasible, secondary surgery has not demonstrated improved survival rates compared to chemotherapy alone in current data.

Conclusions:

• Careful patient selection is crucial to minimize morbidity when considering secondary cytoreductive surgery for recurrent ovarian cancer.
• Further randomized clinical trials are needed to definitively establish the survival benefits of secondary surgery in recurrent ovarian cancer.